HIV transmission at 6 months among those whose diagnostic testing was negative at 6 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission at 6 months among those whose diagnostic testing… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
1 finding from 1 review
HIV transmission at 12 months among those whose diagnostic testing was negative at 6 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers may leads to lower HIV transmission at 12 months among those whose diagnostic testing… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 6 months compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
1 finding from 1 review
Infant Mortality at 12 months · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infant Mortality at 12 months compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
1 finding from 1 review
HIV transmission or Death at 6 months among those whose HIV diagnostic testing was negative at 6 weeks after birth · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in HIV transmission or Death at 6 months among those whose HIV… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (low certainty).
1 finding from 1 review
HIV transmission or death at 12 months among all infants whose HIV diagnostic testing was negative within 6 weeks of birth · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers probably leads to lower HIV transmission or Death at 12 months among those whose HIV… compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (moderate certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes maternal Grade 3/4 Severe Adverse Events compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (very low certainty).
1 finding from 1 review
Infant HIV Transmission or Death at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant HIV Transmission or Death at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at Birth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Birth compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Weeks · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at 6 Weeks compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r may leads to lower mother to Child Transmission at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Mother to Child Transmission at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora continued: AZT/3TC/LPV‐r changes mother to Child Transmission at 12 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Maternal Resistance · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether lehman: AZT/3TC/NVP changes maternal Resistance compared with short Course AZT/sdNVP (very low certainty).
1 finding from 1 review
HIV Transmission or Death at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes infant HIV Transmission or Death at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).
1 finding from 1 review
Stillbirth · ART‐Eligible HIV‐infected Pregnant Women
It is very uncertain whether ekouevi: AZT/3TC/NVP changes stillbirths compared with other Short Course PMTCT Regimen (very low certainty).
1 finding from 1 review
Low birthweight · ART‐Eligible HIV‐infected Pregnant Women
It is very uncertain whether ekouevi: AZT/3TC/NVP changes infant Low Birth Weight compared with other Short Course PMTCT Regimen (very low certainty).
1 finding from 1 review
Mother to Child Transmission at 12 Months · ART‐Eligible HIV‐infected Pregnant Women
It is very uncertain whether ekouevi: AZT/3TC/NVP changes mother to Child Transmission at 12 Months compared with other Short Course PMTCT Regimen (very low certainty).
1 finding from 1 review
HIV Transmission or Death at 1 Month · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes HIV Transmission or Death at 1 Month compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review